{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:01:19Z","timestamp":1790017279792,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Diabetic patients with on-treatment high platelet reactivity (HPR) show an increased risk of thrombotic events. Whether measuring glycated haemoglobin (HbA1c) levels and\/or glycaemic variability (GV) may help identifying diabetic patients at higher risk deserving tailored antiplatelet and\/or glucose lowering strategies is unknown. We aimed to investigate the relationship between GV, HbA1c levels and platelet reactivity in patients with type 2 diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Platelet reactivity was measured in type 2 DM patients using VerifyNow P2Y12 assay. HPR was defined as P2Y12 Reaction Unit (PRU)\u2009&gt;\u2009240. GV was expressed through mean amplitude of glycaemic excursions (MAGE) and coefficient of variance (CV) by using the iPro\u2122 continuous glucose recorder.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-five patients (age 70\u2009\u00b1\u20099\u00a0years, 86% male, mean HbA1c 7.2\u2009\u00b1\u20091.0%) on clopidogrel therapy were enrolled. HbA1c was independently associated with HPR (OR 7.25, 95% CI 1.55\u201333.86, p\u2009=\u20090.012). Furthermore, when factored into the model, GV indexes provided independent (OR 1.094, 95% CI 1.007\u20131.188, p\u2009&lt;\u20090.034) and additional (p\u2009&lt;\u20090.001) diagnostic significance in identifying diabetic patients with HPR.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Glyco-metabolic state significantly correlates with HPR in well-controlled type 2 DM patients on clopidogrel therapy. HbA1c identifies patients at higher thrombotic risk but the highest diagnostic accuracy is achieved by combining GV and HbA1c. Whether individualized antithrombotic and glucose-lowering therapies based on the assessment of these parameters may reduce the incidence of thrombotic events in patients undergoing PCI should be further investigated.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-019-0952-8","type":"journal-article","created":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T08:03:08Z","timestamp":1573286588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5616-3197","authenticated-orcid":false,"given":"Annunziata","family":"Nusca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Tuccinardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Proscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosetta","family":"Melfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Manfrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Nicolucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ceriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Ussia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Grigioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germano","family":"Di Sciascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,9]]},"reference":[{"issue":"12","key":"952_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","volume":"304","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, REACH Registry Investigators, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350\u20137.","journal-title":"JAMA"},{"key":"952_CR2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","volume":"373","author":"M Tancredi","year":"2015","unstructured":"Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbj\u00f6rnsdottir S, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373:1720\u201332.","journal-title":"N Engl J Med"},{"issue":"3","key":"952_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.thromres.2011.11.052","volume":"129","author":"N Vazzana","year":"2012","unstructured":"Vazzana N, Ranalli P, Cuccurullo C, Dav\u00ec G. Diabetes mellitus and thrombosis. Thromb Res. 2012;129(3):371\u20137.","journal-title":"Thromb Res"},{"issue":"16","key":"952_CR4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.jacc.2007.05.049","volume":"50","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Bernardo E, Sabat\u00e9 M, Jimenez-Quevedo P, Costa MA, Palazuelos J, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50(16):1541\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"952_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.atherosclerosis.2011.03.039","volume":"217","author":"S El Ghannudi","year":"2011","unstructured":"El Ghannudi S, Ohlmann P, Jesel L, Radulescu B, El Adraa E, Crimizade U, et al. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention. Atherosclerosis. 2011;217(2):465\u201372.","journal-title":"Atherosclerosis."},{"issue":"11","key":"952_CR6","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1111\/j.1538-7836.2009.03599.x","volume":"7","author":"B Gaborit","year":"2009","unstructured":"Gaborit B, Fr\u00e8re C, Cuisset T, Alessi MC, Dutour A. Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. J Thromb Haemost. 2009;7(11):1939\u201341.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"952_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.thromres.2014.05.010","volume":"134","author":"J Singer","year":"2014","unstructured":"Singer J, Weissler Snir A, Leshem-Lev D, Rigler M, Kornowski R, Lev EI. Effect of intensive glycemic control on platelet reactivity in patients with long-standing uncontrolled diabetes. Thromb Res. 2014;134(1):121\u20134.","journal-title":"Thromb Res"},{"issue":"1","key":"952_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11239-010-0547-4","volume":"32","author":"F Mangiacapra","year":"2011","unstructured":"Mangiacapra F, Peace AJ, Wijns W, Barbato E. Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel. J Thromb Thrombolysis. 2011;32(1):54\u20138.","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"952_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.amjcard.2015.10.037","volume":"117","author":"MM Schoos","year":"2016","unstructured":"Schoos MM, Dangas GD, Mehran R, Kirtane AJ, Yu J, Litherland C, et al. Impact of hemoglobin A1c levels on residual platelet reactivity and outcomes after insertion of coronary drug-eluting stents (from the ADAPT-DES study). Am J Cardiol. 2016;117(2):192\u2013200.","journal-title":"Am J Cardiol"},{"issue":"22","key":"952_CR10","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1001\/jama.2010.785","volume":"303","author":"IB Hirsch","year":"2010","unstructured":"Hirsch IB, Brownlee M. Beyond hemoglobin A1c\u2014need for additional markers of risk for diabetic microvascular complications. JAMA. 2010;303(22):2291\u20132.","journal-title":"JAMA"},{"issue":"1","key":"952_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12933-018-0677-0","volume":"17","author":"CRL Cardoso","year":"2018","unstructured":"Cardoso CRL, Leite NC, Moram CBM, Salles GF. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc Diabetol. 2018;17(1):33.","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"952_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12933-018-0683-2","volume":"17","author":"D Matsutani","year":"2018","unstructured":"Matsutani D, Sakamoto M, Iuchi H, Minato S, Suzuki H, Kayama Y, et al. Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report. Cardiovasc Diabetol. 2018;17(1):36.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"952_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(18)30136-0","volume":"7","author":"A Ceriello","year":"2019","unstructured":"Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2019;7(3):221\u201330.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"952_CR14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.2337\/dc18-2047","volume":"42","author":"E Gerbaud","year":"2019","unstructured":"Gerbaud E, Darier R, Montaudon M, Beauvieux MC, Coffin-Boutreux C, Coste P, et al. Glycemic variability is a powerful independent predictive factor of midterm major adverse cardiac events in patients with diabetes with acute coronary syndrome. Diabetes Care. 2019;42(4):674\u201381.","journal-title":"Diabetes Care"},{"issue":"1","key":"952_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12933-018-0761-5","volume":"17","author":"H Takahashi","year":"2018","unstructured":"Takahashi H, Iwahashi N, Kirigaya J, Kataoka S, Minamimoto Y, Gohbara M, et al. Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome. Cardiovasc Diabetol. 2018;17(1):116.","journal-title":"Cardiovasc Diabetol"},{"key":"952_CR16","doi-asserted-by":"publisher","first-page":"250201","DOI":"10.1155\/2015\/250201","volume":"2015","author":"A Nusca","year":"2015","unstructured":"Nusca A, Lauria Pantano A, Melfi R, Proscia C, Maddaloni E, Contuzzi R, et al. Glycemic variability assessed by continuous glucose monitoring and short-term outcome in diabetic patients undergoing percutaneous coronary intervention: an observational pilot study. J Diabetes Res. 2015;2015:250201.","journal-title":"J Diabetes Res"},{"issue":"5","key":"952_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.4103\/ijem.IJEM_11_18","volume":"22","author":"M Singh","year":"2018","unstructured":"Singh M, Upreti V, Singh Y, Kannapur AS, Nakra M, Kotwal N. Effect of glycemic variability on mortality in ICU settings: a prospective observational study. Indian J Endocrinol Metab. 2018;22(5):632\u20135.","journal-title":"Indian J Endocrinol Metab"},{"issue":"14","key":"952_CR18","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jacc.2008.06.038","volume":"52","author":"G Patti","year":"2008","unstructured":"Patti G, Nusca A, Mangiacapra F, Gatto L, D\u2019Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol. 2008;52(14):1128\u201333.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"952_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","volume":"56","author":"L Bonello","year":"2010","unstructured":"Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919\u201333.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"952_CR20","doi-asserted-by":"publisher","first-page":"e3047","DOI":"10.1002\/dmrr.3047","volume":"34","author":"A Nusca","year":"2018","unstructured":"Nusca A, Tuccinardi D, Albano M, Cavallaro C, Ricottini E, Manfrini S, et al. Glycemic variability in the development of cardiovascular complications in diabetes. Diabetes Metab Res Rev. 2018;34(8):e3047.","journal-title":"Diabetes Metab Res Rev"},{"issue":"Suppl 1","key":"952_CR21","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.2337\/dc18-S006","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Glycemic targets: standards of medical care in diabetes\u20142018. Diabetes Care. 2018;41(Suppl 1):S55\u201364.","journal-title":"Diabetes Care"},{"issue":"5","key":"952_CR22","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.amjcard.2010.04.015","volume":"106","author":"F Mangiacapra","year":"2010","unstructured":"Mangiacapra F, Patti G, Peace A, Gatto L, Vizzi V, Ricottini E, et al. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol. 2010;106(5):619\u201323.","journal-title":"Am J Cardiol"},{"issue":"6","key":"952_CR23","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1161\/CIRCULATIONAHA.106.667741","volume":"115","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007;115(6):708\u201316.","journal-title":"Circulation"},{"issue":"5","key":"952_CR24","doi-asserted-by":"publisher","first-page":"784.e1","DOI":"10.1016\/j.ahj.2009.08.013","volume":"158","author":"A Singla","year":"2009","unstructured":"Singla A, Antonino MJ, Bliden KP, Tantry US, Gurbel PA. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J. 2009;158(5):784.e1\u20136.","journal-title":"Am Heart J"},{"issue":"2","key":"952_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jacc.2006.03.038","volume":"48","author":"DJ Angiolillo","year":"2006","unstructured":"Angiolillo DJ, Bernardo E, Ram\u00edrez C, Costa MA, Sabat\u00e9 M, Jimenez-Quevedo P, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol. 2006;48(2):298\u2013304.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"952_CR26","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","volume":"58","author":"SS Brar","year":"2011","unstructured":"Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol. 2011;58(19):1945\u201354.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"952_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.diabres.2007.01.021","volume":"77","author":"KD Kohnert","year":"2007","unstructured":"Kohnert KD, Augstein P, Heinke P, Zander E, Peterson K, Freyse EJ, et al. Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;77(3):420\u20136.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"952_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.diabet.2018.04.004","volume":"44","author":"H Kahal","year":"2018","unstructured":"Kahal H, Aburima A, Spurgeon B, Wraith KS, Rigby AS, Sathyapalan T, et al. Platelet function following induced hypoglycaemia in type2 diabetes. Diabetes Metab. 2018;44(5):431\u20136.","journal-title":"Diabetes Metab"},{"key":"952_CR29","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S0735-1097(02)02972-8","volume":"41","author":"P Gresele","year":"2003","unstructured":"Gresele P, Guglielmini G, De Angelis M, Ciferri S, Ciofetta M, Falcinelli E, et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol. 2003;41:1013\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"952_CR30","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/j.1538-7836.2010.03742.x","volume":"8","author":"F Santilli","year":"2010","unstructured":"Santilli F, Formoso G, Sbraccia P, Averna M, Miccoli R, Di Fulvio P, et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost. 2010;8(4):828\u201337.","journal-title":"J Thromb Haemost"},{"issue":"9","key":"952_CR31","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jacc.2006.04.102","volume":"48","author":"A Prasad","year":"2006","unstructured":"Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR Jr, Rihal CS. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol. 2006;48(9):1765\u201370.","journal-title":"J Am Coll Cardiol"},{"key":"952_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/XCE.0000000000000145","volume":"7","author":"A Oka","year":"2018","unstructured":"Oka A, Deyama J, Umetani K, Harama T, Shimizu T, Makino A, et al. Glycemic variability is associated with myocardial damage in nondiabetic patients with ST-elevation myocardial infarction. Cardiovasc Endocrinol Metab. 2018;7:47\u201353.","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"6","key":"952_CR33","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1161\/CIRCINTERVENTIONS.110.959080","volume":"3","author":"AJ Lansky","year":"2010","unstructured":"Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circ Cardiovasc Interv. 2010;3(6):602\u201310.","journal-title":"Circ Cardiovasc Interv"},{"key":"952_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12933-015-0275-3","volume":"14","author":"K Okada","year":"2015","unstructured":"Okada K, Hibi K, Gohbara M, Kataoka S, Takano K, Akiyama E, et al. Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes. Cardiovasc Diabetol. 2015;14:111.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"952_CR35","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1160\/TH17-04-0277","volume":"117","author":"MU Zafar","year":"2017","unstructured":"Zafar MU, Baber U, Smith DA, Sartori S, Contreras J, Rey-Mendoza J, et al. Antithrombotic potency of ticagrelor versus clopidogrel in type 2 diabetic patients with cardiovascular disease. Thromb Haemost. 2017;117(10):1981\u20138.","journal-title":"Thromb Haemost"},{"issue":"11","key":"952_CR36","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1161\/CIRCULATIONAHA.116.023402","volume":"134","author":"F Franchi","year":"2016","unstructured":"Franchi F, Rollini F, Aggarwal N, Hu J, Kureti M, Durairaj A, et al. Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (optimizing antiplatelet therapy in diabetes mellitus)-4 study. Circulation. 2016;134(11):780\u201392.","journal-title":"Circulation"},{"key":"952_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.diabres.2018.02.017","volume":"139","author":"M Ohara","year":"2018","unstructured":"Ohara M, Nagaike H, Goto S, Fukase A, Tanabe Y, Tomoyasu M, et al. Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes. Diabetes Res Clin Pract. 2018;139:253\u201361.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"952_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jdiacomp.2009.01.004","volume":"24","author":"R Marfella","year":"2010","unstructured":"Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24 hour acute glucose fluctuations. J Diabetes Complicat. 2010;24(2):79\u201383.","journal-title":"J Diabetes Complicat"},{"issue":"1","key":"952_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/dom.12763","volume":"19","author":"JP Fr\u00edas","year":"2017","unstructured":"Fr\u00edas JP, Nakhle S, Ruggles JA, Zhuplatov S, Klein E, Zhou R, et al. Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017;19(1):40\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"952_CR40","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2018.3024","volume":"319","author":"SL Zheng","year":"2018","unstructured":"Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319(15):1580\u201391.","journal-title":"JAMA"},{"issue":"6","key":"952_CR41","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.2337\/db15-1141","volume":"65","author":"A Cameron-Vendrig","year":"2016","unstructured":"Cameron-Vendrig A, Reheman A, Siraj MA, Xu XR, Wang Y, Lei X, et al. Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis. Diabetes. 2016;65(6):1714\u201323.","journal-title":"Diabetes"},{"issue":"6","key":"952_CR42","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1160\/TH16-07-0586","volume":"117","author":"C Barale","year":"2017","unstructured":"Barale C, Buracco S, Cavalot F, Frascaroli C, Guerrasio A, Russo I. Glucagon-like peptide 1 related peptides increase nitric oxide effects to reduce platelet activation. Thromb Haemost. 2017;117(6):1115\u201328.","journal-title":"Thromb Haemost"},{"issue":"3","key":"952_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1479164118756240","volume":"15","author":"RA Ajjan","year":"2018","unstructured":"Ajjan RA, Cummings MH, Jennings P, Leelarathna L, Rayman G, Wilmot EG. Accuracy of flash glucose monitoring and continuous glucose monitoring technologies: implications for clinical practice. Diabetes Vasc Dis Res. 2018;15(3):175\u201384.","journal-title":"Diabetes Vasc Dis Res"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0952-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-019-0952-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0952-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T00:30:08Z","timestamp":1604795408000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0952-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,9]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["952"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0952-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,9]]},"assertion":[{"value":"1 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Thus study was performed in accordance with the\u00a0Declaration of Helsinki and has been approved by our local Ethic Committee (Ethical Committee of Campus Bio-Medico University of Rome). All subjects enrolled provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}